Objective To investigate the changes in multifocal electroretinography (mfERG)following combined intravitreal Bevacizumab and photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) patients. Methods Prospective study. Thirteen eyes of 13 patients (8 men and 5 women) were recruited for the study. Patients ranged in age from 46 to 71 (60.2±7.7)years.Indocyanine green angiography (ICGA) guided PDT with Verteporfin (6 mg/m2) and was performed according to the recommended standard procedure. Bevacizumab (1.5 mg, 0.06 ml) was injected into the vitreous cavity 3 days later. Visual acuity, fluorescein angiography (FFA) and latencies and average response densities in all 6 rings of mfERG were recorded and compared before treatment and 1, 3 and 6 months after treatment. Results Only one patient needed re-treatment at the 3-month follow-up visit because of persistent leakage on FFA. The mean logMAR visual acuity increased gradually after treatment, and significant increases were observed 3 and 6 months after treatment compared with pre-treatment (Z=-2.823, P=0.005; Z=-2.620, P=0.009). The changes in latencies of the N1 and P1 waves in all 6 rings were not statistically significant. A significant increase in average response densities of both P1 in ring 1 (Z=-2.271, P=0.023) and N1, P1 in ring 2 (Z=-2.202,P=0.028; Z=-1.922, P=0.046) were noted at 3 months post-treatment. The increase in P1 amplitude densities in ring 1(P=0.015) and N1, P1 amplitude densities in ring 2 (Z=-2.158, P=0.031;Z=-2.118, P=0.034) were also significant at 6 months post-treatment. Conclusion Combined intravitreal Bevacizumab and PDT can decrease vessel leakage, improve visual acuity and outer retinal function. mfERG is a good index to evaluate the change in visual function.